We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

17 hedge funds and large institutions have $2.47M invested in Galmed Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

6% less funds holding

Funds holding: 18 → 17 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

31% less capital invested

Capital invested by funds: $3.56M → $2.47M (-$1.09M)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$57.7K
2
WJA
Williams Jones & Associates
New York
+$52.9K
3
CAD
Craig A. Drill
+$52K
4
Deutsche Bank
Deutsche Bank
Germany
+$27.4K
5
MC
Menta Capital
California
+$4.73K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$478K
2
PA
Perceptive Advisors
New York
-$369K
3
KCM
Knoll Capital Management
Florida
-$79.4K
4
DCM
DAFNA Capital Management
California
-$66K
5
Goldman Sachs
Goldman Sachs
New York
-$58K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWAM
1
Park West Asset Management
California
$923K – – –
6CM
2
683 Capital Management
New York
$779K -$478K -506 -34%
KCM
3
Knoll Capital Management
Florida
$224K -$79.4K -84 -23%
SKK
4
Shepherd Kaplan Krochuk
Massachusetts
$144K – – –
CAD
5
Craig A. Drill
$90K +$52K +55 +98%
MC
6
Menta Capital
California
$81K +$4.73K +5 +5%
CA
7
CapWealth Advisors
Tennessee
$54K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$49K +$57.7K +61 New
WJA
9
Williams Jones & Associates
New York
$45K +$52.9K +56 New
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$23K – – –
Deutsche Bank
11
Deutsche Bank
Germany
$23K +$27.4K +29 New
Morgan Stanley
12
Morgan Stanley
New York
$22K – – –
EDRE
13
Edmond de Rothschild (Europe)
Luxembourg
$4K – – –
EDRH
14
Edmond de Rothschild Holding
Switzerland
$4K – – –
Bank of America
15
Bank of America
North Carolina
$2K – – –
RFA
16
Reilly Financial Advisors
California
$1K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$1K +$1.89K +2 New
PA
18
Perceptive Advisors
New York
– -$369K -417 Closed
DCM
19
DAFNA Capital Management
California
– -$66K -75 Closed
Goldman Sachs
20
Goldman Sachs
New York
– -$58K -66 Closed
Barclays
21
Barclays
United Kingdom
– -$10K -13 Closed
UBS Group
22
UBS Group
Switzerland
– -$3K -3 Closed

GLMD Hedge Fund Activity: Q2 2016 in Review

17 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2016, worth a combined $2.47M — down 31% from $3.56M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of GLMD and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $57.7K. The largest seller was 683 Capital Management, cutting an estimated $478K.

  • 17 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2016, down from 18 in Q1 2016.
  • Funds reported $2.47M of Galmed Pharmaceuticals stock for Q2 2016, down 31% quarter-over-quarter.
  • 4 funds opened new Galmed Pharmaceuticals positions in Q2 2016 and 5 closed out, a net change of -1 holder.
  • The largest Galmed Pharmaceuticals buyer in Q2 2016 was Renaissance Technologies, an estimated $57.7K added.
  • The largest Galmed Pharmaceuticals seller in Q2 2016 was 683 Capital Management, an estimated $478K sold.

Based on aggregated 13F filings for Q2 2016.